


IN THE CLAIMS:

Please amend the claims as set forth in the Listing of Claims which replaces all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently amended) A compound having the formula (I):



wherein

X is selected from the radicals $-NR_1-$ and $-CHR_1-$;

Y is independently selected from O and S;

Z is independently selected from a C₁₋₇ straight or C₄₋₈ branched alkylene chain, a C₂₋₇ alkenylene chain and a part of a C₃₋₈ cycloalkyl or C₅₋₈ cycloalkenyl ring structure;

Ar is an aryl group selected from aromatic carbocyclic ring systems, five- or six-membered heteroaromatic ring systems and bicyclic heteroaromatic ring systems;

R₁, R₂ and R₃ are independently selected from a group of substituents (a)-(d) consisting of:

- (a) H;
- (b) C₁₋₆ straight or C₄₋₈ branched chain alkyl;
- (c) C₃₋₈ cycloalkyl or C₅₋₈ cycloalkenyl; and
- (d) C₂₋₆ alkenyl or alkynyl;

wherein the substituents (b)-(d) optionally have at least one substituent independently selected from a group (e)-(i) consisting of:

- (e) Ar, O-Ar or S-Ar;
- (f) OH, O-alkyl or S-alkyl, where alkyl is selected from the substituents (b)-(c);
- (g) NR₄R₅, where R₄ and R₅ are independently selected from the substituents (a)-(d) or optionally together form a nitrogen containing ring structure comprising from 2 to 5 carbon atoms;
- (h) NH-C(O)-alkyl, C(O)-alkyl, O-C(O)-alkyl or S-C(O)-alkyl, where alkyl is selected from the substituents (b)-(c); and
- (i) F, Cl or Br;

R_6 is selected from a group consisting of Ar and the substituents (a)-(c), where (b) and (c) are optionally substituted with at least one of the substituents (e)-(i);

Ar optionally has at least one substituent independently selected from the substituents (b)-(i); and

tautomers, solvates and pharmaceutically acceptable salts of said compound.

2. (Currently amended) The[[A]] compound according to claim 1, wherein X is a radical $-NR_1-$.

3. (Currently amended) The[[A]] compound according to claim 2, wherein R_1 is H.

4. (Currently amended) The[[A]] compound according to ~~any one of claim[[s]] 1[-3]]~~, wherein Y is O.

5. (Currently amended) The[[A]] compound according to ~~any one of claim[[s]] 1[-4]]~~, wherein Ar is selected from phenyl and naphthyl.

6. (Currently amended) The[[A]] compound according to ~~any one of claim[[s]] 1[-5]]~~, wherein Z is selected from $-CH_2-$, $-(CH_2)_2-$, $-(CH_2)_3-$, $-(CH_2)_5-$, $-(CH_2)_6-$, $-(CH_2)_7-$ and *trans*-2-cyclohexylene.

7. (Currently amended) The[[A]] compound according to ~~any one of claim[[s]] 1[-6]]~~, wherein R_6 is selected from isopropyl, cyclopentyl, cyclohexyl, phenyl, 4-*n*-butylphenyl, 4-isopropylphenyl and 2-naphthyl.

8. (Currently amended) The[[A]] compound according to ~~any one of claim[[s]] 1[-7]]~~, wherein R_2 and R_3 are independently selected from H and 4-chlorobenzyl.

9. (Currently amended) The[[A]] compound according to ~~any one of claim[[s]] 1[-8]]~~, wherein the compound is selected from a group consisting of:

4-[3-phenyl-1-(6-phenylhexyl)ureido]butyramide;

4-[1-(4-butylbenzyl)-3-phenylureido]butyramide;

4-[1-(4-isopropylbenzyl)-3-phenylureido]butyramide;

4-[1-(4-methylpentyl)-3-phenylureido]butyramide;

N-(4-chlorobenzyl)-4-[1-(3-cyclohexylpropyl)-3-phenylureido]butyramide;

trans-2-[1-(3-cyclohexylpropyl)-3-phenylureido]cyclohexanecarboxamide;

4-[1-(3-cyclohexylpropyl)-3-naphthalen-2-yl-ureido]butyramide;

4-[1-(2-naphthalen-2-yl-ethyl)-3-phenylureido]butyramide;

4-[1-(2-cyclohexylethyl)-3-phenylureido]butyramide;

4-(1-phenethyl-3-phenylureido)butyramide;

4-(1-benzyl-3-phenylureido)butyramide;

4-[1-(3-cyclopentylpropyl)-3-phenylureido]butyramide;

4-[3-phenyl-1-(5-phenylpentyl)ureido]butyramide; and

4-[1-(3-cyclohexylpropyl)-3-phenylureido]butyramide.

10. (Currently amended) The[[A]] compound according to claim 1, wherein X is a radical $-CHR_1-$.

11. (Currently amended) The[[A]] compound according to claim 10, wherein said radical $-\text{CHR}_1-$ is selected from $-\text{CH}_2-$ and $(R)-\text{CH}(\text{CH}_3)-$.

12. (Currently amended) The[[A]] compound according to ~~any one of claim[[s]] 10[[-11]]~~, wherein Y is O; Ar is selected from phenyl and naphthyl; Z is selected from $-\text{CH}_2-$, $-(\text{CH}_2)_2-$, $-(\text{CH}_2)_3-$, $-(\text{CH}_2)_5-$, $-(\text{CH}_2)_6-$, $-(\text{CH}_2)_7-$ and trans-2-cyclohexylene; R₆ is selected from isopropyl, cyclopentyl, cyclohexyl, phenyl, 4-n-butylphenyl, 4-isopropylphenyl and 2-naphthyl; and R₂ and R₃ are independently selected from H and 4-chlorobenzyl ~~Y, Z, Ar, R₂, R₃ and R₆ are as defined in claims 4-8.~~

13. (Currently amended) The[[A]] compound according to ~~any one of claim[[s]] 10[[-12]]~~, wherein the compound is selected from the[[a]] group consisting of: $(R)-4-[(3\text{-cyclohexylpropyl})-(2\text{-phenylpropionyl})\text{amino}]\text{butyramide}$; $4-[(3\text{-cyclohexylpropyl})-(2\text{-naphthalen-2-yl-acetyl})\text{amino}]\text{butyramide}$; and $8-[(3\text{-cyclohexylpropyl})-(2\text{-naphthalen-2-yl-acetyl})\text{amino}]\text{octanamide}$.

14. (Currently amended) The[[A]] compound according to ~~any one of claim[[s]] 1[[-13]]~~ for use as a pharmaceutical.

15. (Currently amended) A pharmaceutical composition comprising the[[a]] compound according to ~~any one of claim[[s]] 1[[-13]]~~ as active ingredient in association with a pharmaceutically acceptable adjuvant, diluent or carrier.

16. (Currently amended) Use of the[[a]] compound according to ~~any one of claim[[s]] 1[[-13]]~~ for the manufacture of a medicament for treatment of pain and disorders related thereto.

17. (Currently amended) A method for treatment of pain and disorders related thereto, wherein said method comprises administering to an animal, including human, patient of a therapeutically effective amount of the[[a]] compound according to ~~any one of claim[[s]] 1[[-13]]~~.